References
Anna A, Monika G. Splicing mutations in human genetic disorders:
examples, detection, and confirmation. J Appl Genet. 2018
Aug;59(3):253-268. doi: 10.1007/s13353-018-0444-7. Erratum in: J Appl
Genet. 2019 May;60(2):231. PubMed PMID: 29680930; PubMed Central PMCID:
PMC6060985
Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, Estivill X,
Lázaro C. Recurrent mutations in the NF1 gene are common among
neurofibromatosis type 1 patients. J Med Genet. 2003 Jun;40(6):e82. doi:
10.1136/jmg.40.6.e82
Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R,
Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G,
Yoshimura A, Leqius E. 2007. Germline loss‐of‐function mutations in
SPRED1 cause a neurofibromatosis 1‐like phenotype. Nat Genet
39:1120–1126
Cichowski K and Jacks T (2001) NF1 tumor suppressor gene function:
narrowing the GAP. Cell 104:593-604
D’Angelo I, Welti S, Bonneau F, Scheffzek K (2006) A novel bipartite
phospholipid-binding module in the neurofibromatosis type 1 protein.
EMBO Reports 7:174-179
Dufner-Almeida LG, Nanhoe S, Zonta A, Hosseinzadeh M, Kom-Gortat R,
Elfferich P, Schaaf G, Kenter A, Kümmel D, Migone N, Povey S, Ekong R,
Nellist M. Comparison of the functional and structural characteristics
of rare TSC2 variants with clinical and genetic findings. Hum Mutat.
2019 doi:10.1002/humu.23963. PubMed PMID: 31799751
Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K (2016)
The neurofibromin recruitment factor Spred1 binds to the GAP related
domain without affecting Ras activation. Proc. Natl. Acad. Sci.
113:7497-7502
Fadhlullah SFB, Halim NBA, Yeo JYT, Ho RLY, Um P, Ang BT, Tang C, Ng WH,
Virshup DM, Ho IAW (2019) Pathogenic mutations in neurofibromin
identifies a leucine-rich domain regulating glioma cell invasiveness.
Oncogene doi.org/10.1038/s41388-019-0809-3
Führer S, Tollinger M, Dunzendorfer-Matt T (2019) Pathogenic mutations
associated with Legius syndrome modify the Spred1 surface and are
involved in direct binding to the Ras inactivator Neurofibromin. J. Mol.
Biol. 431:3889-3899
Geist RT, Gutmann DH (1996) Expression of a developmentally-regulated
neuron-specific isoform of the neurofibromatosis 1 (NF1) gene. Neurosci
Lett. 211(2):85-8. PubMed PMID: 8830850
Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA 3rd, Smith HO
(2009) Enzymatic assembly of DNA molecules up to several hundred
kilobases. Nat Methods. 6(5):343-5. doi: 10.1038/nmeth.1318. Epub 2009
Apr 12. PMID: 19363495
Halim D, Brosens E, Muller F, Wangler MF, Beaudet AL, Lupski JR, Akdemir
ZHC, Doukas M, Stoop HJ, de Graaf BM, Brouwer RWW, van Ijcken WFJ, Oury
JF, Rosenblatt J, Burns AJ, Tibboel D, Hofstra RMW, Alves MM (2017)
Loss-of-Function Variants in MYLK Cause Recessive Megacystis Microcolon
Intestinal Hypoperistalsis Syndrome. Am J Hum Genet. 101:123-129
HGVS Recommendations for the Description of Sequence Variants: 2016
Update Hum Mutat. 2016 Jun;37(6):564-9
Hirata Y, Brems H, Suzuki M, Kanamori M, Okada M, Morita R, Llano-Rivas
I, Ose T, Messiaen L, Legius E, Yoshimura A (2016) Interaction between a
domain of the negative regulator of the RAS-ERK pathway, SPRED1 protein,
and the GTPase-activating protein-related domain of neurofibromin is
implicated in Legius syndrome and neurofibromatosis type 1. J. Biol.
Chem. 291:3124-3134
Hoogeveen-Westerveld M, van Unen L, van den Ouweland A, Halley D,
Hoogeveen A, Nellist M. (2012) The TSC1-TSC2 complex consists of
multiple TSC1 and TSC2 subunits. BMC Biochem . 13 e18
Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis
1. Genet Med 2010: 12 (1): 1-11
Koczkowska M, Callens T, Gomes A, Sharp A, Chen Y, Hicks AD, Aylsworth
AS, Azizi AA, Basel DG, Bellus G, Bird LM, Blazo MA, Burke LW, Cannon A,
Collins F, DeFilippo C, Denayer E, Digilio MC, Dills SK, Dosa L,
Greenwood RS, Griffis C, Gupta P, Hachen RK, Hernández-Chico C, Janssens
S, Jones KJ, Jordan JT, Kannu P, Korf BR, Lewis AM, Listernick RH,
Lonardo F, Mahoney MJ, Ojeda MM, McDonald MT, McDougall C, Mendelsohn N,
Miller DT, Mori M, Oostenbrink R, Perreault S, Pierpont ME, Piscopo C,
Pond DA, Randolph LM, Rauen KA, Rednam S, Rutledge SL, Saletti V,
Schaefer GB, Schorry EK, Scott DA, Shugar A, Siqveland E, Starr LJ, Syed
A, Trapane PL, Ullrich NJ, Wakefield EG, Walsh LE, Wangler MF, Zackai E,
Claes KBM, Wimmer K, van Minkelen R, De Luca A, Martin Y, Legius E,
Messiaen LM (2019) Expanding the clinical phenotype of individuals with
a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of
genotype-phenotype correlation. Genet Med. 21(4):867-876. doi:
10.1038/s41436-018-0269-0. PMID: 30190611
Koczkowska M, Callens T, Chen Y, Gomes A, Hicks AD, Sharp A, Johns E,
Uhas KA, Armstrong L, Bosanko KA, Babovic-Vuksanovic D, Baker L, Basel
DG, Bengala M, Bennett JT, Chambers C, Clarkson LK, Clementi M, Cortés
FM, Cunningham M, D’Agostino MD, Delatycki MB, Digilio MC, Dosa L,
Esposito S, Fox S, Freckmann ML, Fauth C, Giugliano T, Giustini S,
Goetsch A, Goldberg Y, Greenwood RS, Griffis C, Gripp KW, Gupta P, Haan
E, Hachen RK, Haygarth TL, Hernández-Chico C, Hodge K, Hopkin RJ,
Hudgins L, Janssens S, Keller K, Kelly-Mancuso G, Kochhar A, Korf BR,
Lewis AM, Liebelt J, Lichty A, Listernick RH, Lyons MJ, Maystadt I,
Martinez Ojeda M, McDougall C, McGregor LK, Melis D, Mendelsohn N,
Nowaczyk MJM, Ortenberg J, Panzer K, Pappas JG, Pierpont ME, Piluso G,
Pinna V, Pivnick EK, Pond DA, Powell CM, Rogers C, Ruhrman Shahar N,
Rutledge SL, Saletti V, Sandaradura SA, Santoro C, Schatz UA, Schreiber
A, Scott DA, Sellars EA, Sheffer R, Siqveland E, Slopis JM, Smith R,
Spalice A, Stockton DW, Streff H, Theos A, Tomlinson GE, Tran G, Trapane
PL, Trevisson E, Ullrich NJ, Van den Ende J, Schrier Vergano SA, Wallace
SE, Wangler MF, Weaver DD, Yohay KH, Zackai E, Zonana J, Zurcher V,
Claes KBM, Eoli M, Martin Y, Wimmer K, De Luca A, Legius E, Messiaen LM.
(2020) Clinical spectrum of individuals with pathogenic NF1 missense
variants affecting p.Met1149, p.Arg1276, and p.Lys1423:
genotype-phenotype study in neurofibromatosis type 1. Hum Mutat. 2020
Jan;41(1):299-315. doi: 10.1002/humu.23929
Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y,
Blakeley J, Babovic-Vuksanovic D, Soares Cunha K, Ferner R, Fisher MJ,
Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner V-F,
Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A,
Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K,
International Consensus Group on Neurofibromatosis Diagnostic Criteria,
Huson SM, Evans DG, Plotkin SR (2021) Revised diagnostic criteria for
neurofibromatosis type 1 and Legius syndrome: an international consensus
recommendation. Genet Med. 23(8):1506-1513. doi:
10.1038/s41436-021-01170-5
Ly KI, Blakeley JO (2019) The Diagnosis and Management of
Neurofibromatosis Type 1. Med Clin North Am. 2019 Nov;103(6):1035-1054.
doi: 10.1016/j.mcna.2019.07.004
Mattocks C, Baralle D, Tarpey P, ffrench-Constant C, Bobrow M, Whittaker
J. Automated comparative sequence analysis identifies mutations in 89%
of NF1 patients and confirms a mutation cluster in exons 11-17 distinct
from the GAP related domain. J Med Genet. 2004 Apr;41(4):e48. PubMed
PMID: 15060124; PubMed Central PMCID: PMC1735749
Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N,
Speleman F, Paepe AD. Exhaustive mutation analysis of the NF1 gene
allows identification of 95% of mutations and reveals a high frequency
of unusual splicing defects. Hum Mutat. 2000;15(6):541-55. doi:
10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N.
PMID: 10862084Peltonen S., Pöyhönen M. Clinical diagnosis and atypical
forms of NF1. In: Upadhyaya M., Cooper D.N., editors. Neurofibromatosis
Type 1. Molecular and Cellular Biology. Springer-Verlag Berlin
Heidelberg; 2012. pp. 17–30
Ratner N, Miller SJ (2015) A RASopathy gene commonly mutated in cancer:
the neurofibromatosis type 1 tumour suppressor. Nature Reviews Cancer
15:290-301
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW,
Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) Standards and
guidelines for the interpretation of sequence variants: a joint
consensus recommendation of the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology. Genet. Med.
17:405-423
Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P,
Waterfield MD, Ridley A, Downward J. (1997) Role of phosphoinositide
3-OH kinase in cell transformation and control of the actin cytoskeleton
by Ras. Cell.89:457-467Sambrook J, Fritsch EF, Maniatis T (1989)
Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory
Press Thomas L, Richards M, Mort M, Dunlop E, Cooper DN, Upadhyaya M
(2012) Assessment of the potential pathogenicity of missense mutations
identified in the GTPase-activating protein (GAP)-related domain of the
neurofibromatosis type-1 (NF1 ) gene. Hum. Mutat. 33:1687-1696
Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernandez H,
Burlingame AL, McCormick F (2012) A shared molecular mechanism underlies
the human raspoathies Legius syndrome and neurofibromatosis-1. Genes
Dev. 26: 1421-1426
van Minkelen R, van Bever Y, Kromosoeto JN, Withagen-Hermans CJ,
Nieuwlaat A, Halley DJ, van den Ouweland AM. Clin Genet. 2014
Apr;85(4):318-27
van Triest M, de Rooij J, Bos JL. Measurement of GTP-bound Ras-like
GTPases by activation-specific probes. Methods Enzymol. 2001;333:343-8.
PubMed PMID:11400350
Welti S, Kuhn S, D’Angelo I, Brugger B, Kaufmann D, Scheffzek K (2011)
Structural and biochemical consequences of NF1 associated nontruncating
mutations in the Sec14-PH module of neurofibromin. Hum. Mutat.
32:191-197
Xiao H, Yuan L, Xu H, Yang Z, Huang F, Song Z, Yang Y, Zeng C, Deng H.
(2018) Novel and Recurring Disease-Causing NF1 Variants in Two Chinese
Families with Neurofibromatosis Type 1. J Mol Neurosci. 65:557-563
Yan W, Markegard E, Dharmaiah S, Urisman A, Drew M, Esposito D,
Scheffzek K, Nissley DV, McCormick F, Simanshu DK (2020) Structural
Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of
SPRED1-Neurofibromin Interaction by Oncogenic EGFR. Cell Rep. 2020 Jul
21;32(3):107909. doi: 10.1016/j.celrep.2020.107909
Zatkova A, Messiaen L, Vandenbroucke I, Wieser R, Fonatsch C, Krainer
AR, Wimmer K. Disruption of exonic splicing enhancer elements is the
principal cause of exon skipping associated with seven nonsense or
missense alleles of NF1. Hum Mutat. 2004 Dec;24(6):491-501. doi:
10.1002/humu.20103